The day-hospital operator continued to incur losses at its SA operations in its six months to end-December, but moved closer to breaking even
Changes in consumer behaviour continue to put pressure on the group, but it has proceeded with an interim dividend and is looking to grow
Discovery says Quantum Medical is unlikely to be sustainable over the long term due to falling membership, which has been worsened by Covid-19
Attridge will commence a new role at Aspen in 2022, which will include supporting and mentoring the executive team
The EU executive is concerned that Aspen may have charged excessive prices for drugs mainly used to treat leukaemia and other haematological cancers
Investigation reveals consensual though inappropriate personal communications with staff
SPONSORED | Vital Health Foods provides staff with vitamins and supplements as part of its wellness campaign
The rise of new coronavirus strains has prompted calls for vaccinating people more quickly before mutations can become widespread
Covid-19 continues to weigh on the group, which says it had more pandemic patients in the three months to end-December than in the prior seven
CEO Anne Wojcicki says Covid-19 has opened doors to more health-care products including genetic data
MIG has provided funding to the German biotech company, which developed the vaccine with US drugmaker Pfizer, since 2008
Frazier, one of just four black CEOs in the Fortune 500, assumed a national profile in the US as he spoke out about race and racism, and left Trump's business ...
Cambridge-based GW Pharma’s US-traded shares surge nearly 50%
Pfizer is commanding a higher price for its vaccine than some rivals
The health-focused group says its portfolio of assets has fared well during the pandemic
The process is part of the original contract but the EU sees it hampering its already slow Covid-19 vaccine rollout
In a sub-study of 6,000 volunteers in SA, the vaccine was 89% effective, with 95% of cases in the SA trial infected with the SA variant
Hospital occupancies enjoyed a healthy improvement in October and November as elective surgeries picked up
Company set an annual target for the key performance measure at $2.5bn-$4.5bn
Two lenders seem to have come to its rescue, offering the prospect of a recapitalisation without disposals
